BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32861103)

  • 1. Multimodal dopamine transporter (DAT) imaging and magnetic resonance imaging (MRI) to characterise early Parkinson's disease.
    Porter E; Roussakis AA; Lao-Kaim NP; Piccini P
    Parkinsonism Relat Disord; 2020 Oct; 79():26-33. PubMed ID: 32861103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of the nigrostriatal system for evaluating the preclinical phase of Parkinson's disease development: the utility of neuromelanin, diffusion MRI, and DAT-SPECT.
    Takahashi H; Kashiwagi N; Arisawa A; Matsuo C; Kato H; Adachi H; Kajiyama Y; Mochizuki H; Tomiyama N
    Br J Radiol; 2022 Feb; 95(1130):20210837. PubMed ID: 34808066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease.
    Meles SK; Oertel WH; Leenders KL
    Mol Med; 2021 Sep; 27(1):111. PubMed ID: 34530732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Principal Component Analysis of Multimodal Neuromelanin MRI and Dopamine Transporter PET Data Provides a Specific Metric for the Nigral Dopaminergic Neuronal Density.
    Kawaguchi H; Shimada H; Kodaka F; Suzuki M; Shinotoh H; Hirano S; Kershaw J; Inoue Y; Nakamura M; Sasai T; Kobayashi M; Suhara T; Ito H
    PLoS One; 2016; 11(3):e0151191. PubMed ID: 26954690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nigrostriatal dopamine transporter availability in early Parkinson's disease.
    Fazio P; Svenningsson P; Cselényi Z; Halldin C; Farde L; Varrone A
    Mov Disord; 2018 Apr; 33(4):592-599. PubMed ID: 29436751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine Transporter Imaging in Parkinson Disease: Progressive Changes and Therapeutic Modification after Anti-parkinsonian Medications.
    Ikeda K; Ebina J; Kawabe K; Iwasaki Y
    Intern Med; 2019 Jun; 58(12):1665-1672. PubMed ID: 30799370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relations of clinical symptoms with dopamine transporter imaging in drug-naïve Parkinson's disease.
    Mito Y; Yabe I; Yaguchi H; Sato C; Takei T; Terae S; Tajima Y
    Clin Neurol Neurosurg; 2020 Sep; 196():105960. PubMed ID: 32593043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fractional Anisotropy and Mean Diffusion as Measures of Dopaminergic Function in Parkinson's Disease: Challenging Results.
    Lenfeldt N; Eriksson J; Åström B; Forsgren L; Mo SJ
    J Parkinsons Dis; 2017; 7(1):129-142. PubMed ID: 28106567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
    Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
    Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments.
    Rahmim A; Salimpour Y; Jain S; Blinder SA; Klyuzhin IS; Smith GS; Mari Z; Sossi V
    Neuroimage Clin; 2016; 12():e1-e9. PubMed ID: 27995072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct dopaminergic abnormalities in traumatic brain injury and Parkinson's disease.
    Jenkins PO; Roussakis AA; De Simoni S; Bourke N; Fleminger J; Cole J; Piccini P; Sharp D
    J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):631-637. PubMed ID: 32381639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions.
    Park SB; Kwon KY; Lee JY; Im K; Sunwoo JS; Lee KB; Roh H; Ahn MY; Park S; Kim SJ; Oh JS; Kim JS
    Neurol Sci; 2019 Feb; 40(2):311-317. PubMed ID: 30415448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling correlative roles of dopamine transporter (DAT) and Parkin in Parkinson's disease (PD) - A road to discovery?
    Jayaramayya K; Iyer M; Venkatesan D; Balasubramanian V; Narayanasamy A; Subramaniam MD; Cho SG; Vellingiri B
    Brain Res Bull; 2020 Apr; 157():169-179. PubMed ID: 32035946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of the combined use of
    Matsusue E; Fujihara Y; Tanaka K; Aozasa Y; Shimoda M; Nakayasu H; Nakamura K; Ogawa T
    Acta Radiol; 2019 Feb; 60(2):230-238. PubMed ID: 29804474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance and dopamine transporter imaging for the diagnosis of Parkinson´s disease: a narrative review.
    Otani RTV; Yamamoto JYS; Nunes DM; Haddad MS; Parmera JB
    Arq Neuropsiquiatr; 2022 May; 80(5 Suppl 1):116-125. PubMed ID: 35976320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of striatal dopamine depletion on cognition in de novo Parkinson's disease.
    Chung SJ; Yoo HS; Oh JS; Kim JS; Ye BS; Sohn YH; Lee PH
    Parkinsonism Relat Disord; 2018 Jun; 51():43-48. PubMed ID: 29526657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An
    Joling M; Vriend C; Raijmakers PGHM; van der Zande JJ; Lemstra AW; Berendse HW; Booij J; van den Heuvel OA
    Neuroimage Clin; 2019; 22():101755. PubMed ID: 30884365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined use of dopamine transporter imaging (DAT-SPECT) and
    Yoshii F; Ryo M; Baba Y; Koide T; Hashimoto J
    J Neurol Sci; 2017 Apr; 375():80-85. PubMed ID: 28320195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.